SUMMARY.-The records of 1243 patients with myasthenia gravis (M.G.) have been reviewed in a retrospective study of the incidence of extrathymic neoplasms. Ninety-four malignant neoplasms were traced.
CLINICAL MATERIAL AND METHODS
The records of 1243 The patients were separated into four categories according to the presence or absence of thymomas, and whether or not they had undergone thymectomy (Table I ). The foUowing factors pertaining to the occurrence of neoplasia were studied: the crude incidence of malignant neoplasms in each of the four categorieg, the primary sites, the interval between the diagnosis and the onset of symptoms Extrathymic malignancie,8
An overall incidence of 7-5% of extrathymic malignancies was noted; the incidence was 7-4% for the non-thymomatous and 8-9% for the thymomatous group.
The primary sites are shown in Table 111 ; 31 of these occurred in men and 63 in women. Breast was the most common primary site (40% of all neoplasms in myasthenic women). Frequent occurrence of multiple extrathymic neoplasdis was noted in myasthenic women who had not undergone thymectomy (8 patients).
The age of diagnosis of the extrathymic neoplasms is shown in Fig. I and compared with the age of onset of M.G. in the 1243 patients. Fig. 2 shows the interval between the diagnosis of the neoplasms and the onset of M.G. (Table 11 ), the expected number of extrathymic neoplasms is 56; in fact 25 were observed. By contrast, the observed number of neoplasms for M.G. non-thymectomy period (64) was considerably higher than the expected (28). Fig. 3 shows that the annual incidence of neoplasms increased sharply with the onset of M.G. and remained high throughout the duration of the disease in patients who did not undergo thymectomy. Of the 64 neoplasms that occurred in the M.G. non-thymectomy period 39 were in women and 25 in men; the expected figures are 14 and 14 respectively. Following thymectomy, however, the annual incidence decreased to expected levels (Fig. 4) . diagnosed in the first two postoperative years. In the second five-year period after thymectomy, the incidence of neoplasms was not increased.
In the control group of hernia patients, the highest annual incidence of cancer occurred in the year following admission for hernia repair. However, even in that year the actual incidence was only slightly higher than the expected: (actual 5-26%0, expected 5-03%0) in contrast to the three-fold increase that occurred in -the M.G. patients (Fig. 3) . Furthermore, there was no sharp difference in the actual incidence between the period before, and that following the year of herniorrhaphy. By contrast, in the second control group the incidence of neoplasms before the onset of the regional enteritis and/or granulomatous enterocolitis was below the (Keynes, 1969) .
The reported incidence of extrathymic neoplasms in patients with M.G. varies between 1-4% and 2-5% and the association has until now been considered to be fortuitous (Lambert and Rooke, 1965) . Osserman (1958) reported eight malignancies among 325 patients with myasthenia gravis (2-5%). Lambert and Rooke (1965) The frequency of breast cancer is noteworthy. In our series a high incidence was observed in all three risk periods. A separate study on the relationship of breast cancer and thymic abnormalities is to be reported.
The overall incidence of multiple neoplasms in M.G. patients (10-5%) was also higher than the 5-1 % reported incidence for multiple primaries (Moertel, 1966) , and the ratio of deaths from extrathymic neoplasms to all non-myasthenic deaths was also elevated. All multiple neoplasms and all neoplastic deaths occurred in nonthymectomy patients.
The 7-5% incidence of extrathymic neoplasms in the present series is considerably higher than that previously reported in M.G. patients. This increase has been present in both the thymomatous (8-9%) and the non-thymomatous (7-3%) M.G. patients. The period of highest risk was the one after the onset of M.G. and before thymectomy (observed neoplasms 64, expected 28).
In the period preceding the onset of M.G. the low incidence of neoplasms might be partly attributable to the omission of persons who developed cancer and died, who, had they lived, might have developed M.G. This weakness, however, also exists in any age specific study of the incidence of cancer, in that patients who die from any cause before reaching the age group under study are excluded. In the M.G. non-thymectomy period a similar problem exists: (a) since M.G. has a high mortality, particular in the first three years of the disease, Simpson, 1958 ) the non-survivors who might have developed cancer are excluded from the study; (b) more than one-half of the 1243 patients were first seen at Mount Sinai Hospital after the fifth year from the onset of the disease, therefore patients who had cancer and died in the first five years of the disease are also excluded from this sample. For these reasons underestimation of the cancer incidence in the M.G. non-thymectomy period is as probable as in the period before the onset of M.G.
Because of these limitations and for the reasons described below, we have studied the incidence of neoplasms in two control groups. The herniorrhaphy group was included to evaluate whether the annual incidence of cancer in our hospital population undergoing a complete workup on admission and under close observation for a year in follow-up clinic, is significantly higher than that expected in a sex and age matched group of the general population. The differences and the peculiarities in cancer incidence of a hospital population compared with the general population are well known (Lilienfeld et al., 1967) . The incidence of cancer in the herniorrhaphy group in the year of admission was only slightly higher than that expected, while a three-fold increase in cancer incidence in the M.G. population for the year of the onset of the disease was observed. Furthermore, in the hernia group there was no difference in the incidence of cancer in the preand post-herniorrhaphy periods.
The M.G. and the hernia patients are not strictly comparable populations, some of the former being referred to the hospital from out of state or overseas, while the latter represent a cross section of the population of New York City. Yet the comparison shows that the sharp increase of cancer coinciding with the onset of M.G. probably cannot be attributed only to the close follow-up of a hospital population.
The second control group was chosen to evaluate whether the M.G. pattern of cancer incidence (Fig. 3) is present in other chronic diseases in which autoimmune mechanisms are implicated. A pattern similar to that observed in myasthenic patients was found in that group, i.e. increase in cancer incidence coinciding with the onset of the disease. However, the increase over the expected incidence for the period following the diagnosis of regional enteritis was only one-half the observed increase in the M.G. non-thymectomy period. This study is still in progress and will be reported separately in detail.
It would seem, therefore, that the increase of cancer incidence in the M.G. non-thymectomy period (Fig. 3) is not attributable to the bias of a retrospective study, nor to the variations and peculiarities inherent in a study of a hospital population, but is rather a characteristic of the disease itself.
The cancer incidence in the post-thymectomy period showed a marked decline after the second post-operative year. Because of the four neoplasms that occurred during the first two post-operative years and the small number of person-years of observation, the risk in the first five post-operative years remained elevated, while the annual incidence of neoplasms in the second five-years post-thymectomy period fell to the expected levels of the general population.
In a thymectomy series with a longer follow-up (average 12 years) reported by Doll and Kinlen (1970) the cancer incidence was within the expected general population levels.
The findings of an increased incidence during the M.G. non-thymectomy period, together with the observed decrease following thymectomy (Fig. 4) , suggests that the abnormal thymus plays an oneogenic role. Other evidence of th'ymic involvement in human oncogenesis has been provided by (1) the increased incidence of reticuloendothelial malignancies in patients with poorly developed or involuted thymus glands (primary immunological deficienev svnd-rome: Ataxia Telangiectasia of Louis-Bar and the non-sex linked immunoglobulin deficiencies) (Alexander and Good, 1970) ; (2) the frequent occurrence of extrathymic neoplasms, particularly of the reticuloendothelial system in patients with autoimmune diseases: rheumatoid arthritis (Blumenthal and Berns, 1966; Goldenberg et al., 1969 ), Sjorgen's syndrome (Talal and Bunin, 1966) , autoimmune anemias (Pirofsky, 1968) and lupus erythematosus (Miller, 1967) . Thymic pathology is a common finding in these diseases (Miller, 1965) either in the form of thymic hyperplasia with germinal center formation and/or epithelial, lymphoepithelial or spindle cell thymomas.
The coexistence of immunological deficiencies, autoimmune diseases and neoplasia in patients with thymic pathology has led to the suggestion by Miller (1967) that persistent thymic abnormalities might be associated with diminished resistance to some types of neoplasia. Thomas (1959) postulated that the function of cellular immunity is the recognition and rejection of mutant cells as foreign, and the thymic control mechanism against neoplasia was termed immunosurveillance by Burnet (1967) . In Good's view the surveillance system permits cells whieb are prone to develop malignancy to function to the advantage rather than disadvantage of the host (Good and Finstad, 1968) . The suggestion has been made that this immunosurveillant mechanism is mediated by the small lymphocytes of thymic origin which are capable of expressing immune responses (Burnet, 1967) . The increased frequency of tumors is a recognized hazard of impaired immunosurveillance (Lawrence, 1970) , and the increase of cancer in elderly patients may be attributed to a decreased activity of the thymic immunosurveillance (Walford, 1969) .
The clonal theories of autoimmunity (Burnet, 1959 (Burnet, , 1965 Burch and Burwell, 1965) have attributed autoimmune manifestations to the proliferation of mutant self-reacting clones of immunocompetent lymphocytes that escape the recognition mechanism of thymic immunosurveillance, thus proliferating and reacting against target organs of the host.
Clinical evidence supporting these theories has been provided by the observations that thymectomy in myasthenia gravis results in stable and permanent remissions, and that the delay in the onset of these remissions is directly related to theactivityofthethymicgernimalcenters (Papatestasetal.,1971) . Thisobserva- tion, originally made on 64 M.G. patients, has been confirmed in a larger series (Perlo et al., in press). Since thymic germinal centers are viewed as possible centers of proliferation of " forbidden " clones (Burnet and Holmes, 1966) , the effects of thymectomy in M.G. could be attributed to the elimination of the sites of proliferation of these clones .
Thymectomy in experimental animals is not always followed by an increased incidence of neoplasia; the reduced occurrence of neoplasms such as mammary tumors (Allison and Taylor, 1967; Yunis et al., 1969) , lymphomas and lymphoid leukemia (Miller, 1961) following experimental thymectomy suggest that the thymus plays an oneogenic role, in addition to its immunosurveillant one.
It is possible that both these roles are mediated through the small immunocompetent lymphocytes of thymic origin; the allogeneic behaviour of the abnormal self-reacting clones of thymic lymphocytes might well have an oncogenic potential since allogeneic lymphocytes have been shown to promote chromosomal aberrations (Fialkow, 1967) and to induce neoplasia in experimental animals (Schwa'rtz and Beldotti, 1965; Lancet, 1969) . Therefore, the increased incidence of neoplasia in autoimmune disease could be linked to the allogeneic behaviour of the selfreacting clones.
The reported frequent occurrence of neoplasms in target organs of autoimmune disorders-thymomas in myasthenia gravis, colonic carcinomas in 'ulcerative colitis and thyroid carcinomas in thyroiditis (Blumenthal and Berns, 1966) -is consistent with an oneogenic role for the abnormal clones.
In the light of these observations further study of the thymic role in autoimmunity and human oncogenesis is indicated.
